Armata Pharma (ARMP): Bathi resik saben saham (EPS TTM)

Armata Pharmaceuticals management relies on scientific potential and external investments while drugs undergo clinical trials. This 12-month net income per share chart visualizes the results of this work, where the -7.06 level represents the current value. The business is not influenced by GDP, yet it requires expensive cold-chain logistics to preserve the properties of bacteriophages.

Since Armata Pharmaceuticals' bacteriophage development does not yet generate revenue, the company's pricing power is limited by the clinical trial stage. The current value of -7.06 reflects the trailing twelve-month net income per share, allowing investors to filter out market noise and assess the business's actual capital by analyzing the trailing annual EPS trend to identify undervaluation points.